USPTO serial 79377424
BIOXPEDIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 14, 2025
- Examiner
- SWAIN, MICHELE LYNN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIOXPEDIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rhett V. Barney
Rhett V. Barney Lee & Hayes, PC601 W. Riverside Ave. Suite 1400Kungsgatan 42Spokane, WA 99201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Provision of business statistical information relating to medical matters; compilation of statistical data relating to medical research for business purposes; compilation of statistics for business purposes; business assistance, management and administrative services; compilation of medical reports for business purposes | ACTIVE | — |
| 042 | Analytical laboratory services, namely, laboratory research services in the field of biomarker discovery and validation for drug development; scientific and technological services, namely, providing assays and analytical methods for clinical research, drug discovery, and development; research relating to molecular sciences, specifically research involving molecular diagnostics, genomics, and proteomics for personalized medicine; genetic research specifically human genetic research focusing on gene expression profiling, genome-wide association studies, and genetic biomarker discovery; biological analysis; medical and pharmacological research services; biology consultancy; biological research; biological development services specifically development and optimization of biological assays and protocols for preclinical and clinical trials; biochemistry research services; laboratory services specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, ELISA; laboratory services, specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, dPCR, ELISA; biomedical research services; structural and functional analysis of genomes; natural science services, namely, natural science services, namely, scientific research in the fields of biochemistry, molecular biology, and pharmacology; medical research; medical research laboratory services; research in the field of gene therapy, including vector development, gene editing, and delivery mechanisms for therapeutic purposes; scientific research in the field of genetics; laboratory research in the field of gene expression; research in the field of gene editing technology, particularly using CRISPR-Cas9 and other gene-editing tools for therapeutic applications and functional genomics studies; scientific research for medical purposes in the area of cancerous diseases; dna conducting of scientific feasibility studies; DNA screening for scientific research purposes; DNA analysis to determine paternity; research and development services in the field of gene expression systems; analysis of human serum for medical research; analysis of human tissues for medical research; scientific research relating to the isolation and cultivation of human tissues and cells; cell culture services for scientific and research purposes, for others; toxicity analysis, namely, in vitro and in vivo toxicity testing of pharmaceuticals and chemical compounds for safety and efficacy assessments; toxicity testing for scientific research purposes; testing of pharmaceuticals for scientific research; blood analysis services for scientific research purposes | ACTIVE | — |
| 044 | Human healthcare services; medical laboratory analysis services relating to the treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical laboratory services for the analysis of blood samples taken from patients; medical analysis services relating to the treatment of persons provided by a medical laboratory; medical services; medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical consultations; medical information; medical diagnostic services; medical counseling; providing medical information; issuing of medical reports; genetic testing for medical purposes; medical and health services relating to dna, genetics and genetic testing; medical analysis services for the diagnosis of cancer; DNA screening for medical purposes; RNA and DNA analysis for cancer diagnosis and prognosis for medical purposes; analysis of human serum for medical treatment; medical testing of urine; analysis of human tissues for medical treatment; medical treatment using cultured cells; cultured cell bank services for medical transplantation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioXpedia A/S
- Other trademarks owned by BioXpedia A/S
- Other trademarks owned by BioXpedia A/S
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BIOXPEDIA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 8, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 21, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 21, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 14, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 15, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 26, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 14, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 14, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 26, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 26, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 20, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 18, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 18, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 18, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 19, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 19, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 28, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 27, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 22, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 25, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 5, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 31, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |